Manzato M, Wright R, Jaffe A, Vasile V
Rev Cardiovasc Med. 2024; 25(11):393.
PMID: 39618878
PMC: 11607505.
DOI: 10.31083/j.rcm2511393.
Manzato M, Meeusen J, Donato L, Jaffe A, Vasile V
Am J Prev Cardiol. 2024; 20:100886.
PMID: 39507938
PMC: 11539117.
DOI: 10.1016/j.ajpc.2024.100886.
Bellomo T, Liu Y, Gilliland T, Miksenas H, Haidermota S, Wong M
J Lipid Res. 2024; 65(7):100585.
PMID: 38942114
PMC: 11298641.
DOI: 10.1016/j.jlr.2024.100585.
Wang G, Xia M, Liang C, Pu F, Liu S, Jia D
Front Cardiovasc Med. 2024; 11:1362893.
PMID: 38784168
PMC: 11112025.
DOI: 10.3389/fcvm.2024.1362893.
Chandra M, Paray A
Yale J Biol Med. 2024; 97(1):85-92.
PMID: 38559455
PMC: 10964813.
DOI: 10.59249/JTIV4138.
Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults.
Yuen T, Mancini G, Hegele R, Pearson G
CJC Open. 2024; 6(3):597-606.
PMID: 38559332
PMC: 10980900.
DOI: 10.1016/j.cjco.2023.11.015.
Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.
Dai W, Castleberry M, Zheng Z
J Thromb Haemost. 2023; 21(10):2679-2696.
PMID: 37579878
PMC: 10599797.
DOI: 10.1016/j.jtha.2023.08.004.
Inverse Association of Lipoprotein(a) on Long-Term Bleeding Risk in Patients with Coronary Heart Disease: Insight from a Multicenter Cohort in Asia.
Wang P, Yuan D, Zhao X, Zhu P, Guo X, Jiang L
Thromb Haemost. 2023; 124(7):684-694.
PMID: 37487540
PMC: 11199048.
DOI: 10.1055/s-0043-1771188.
Molecular Biomarkers for Cardiometabolic Disease: Risk Assessment in Young Individuals.
Tahir U, Gerszten R
Circ Res. 2023; 132(12):1663-1673.
PMID: 37289904
PMC: 10320574.
DOI: 10.1161/CIRCRESAHA.123.322000.
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.
Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S
Molecules. 2023; 28(3).
PMID: 36770634
PMC: 9918959.
DOI: 10.3390/molecules28030969.
Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.
Tyagi R, Vaidya B, Sharma S
Pharmacol Rep. 2022; 74(5):790-817.
PMID: 36149598
DOI: 10.1007/s43440-022-00417-5.
Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis-From Pathophysiology to Therapeutic Implications.
Badescu M, Rezus E, Ciocoiu M, Badulescu O, Butnariu L, Popescu D
Int J Mol Sci. 2022; 23(2).
PMID: 35054824
PMC: 8776054.
DOI: 10.3390/ijms23020640.
Functions of the plasminogen receptor Plg-R.
Miles L, Vago J, Sousa L, Parmer R
J Thromb Haemost. 2020; 18(10):2468-2481.
PMID: 32662180
PMC: 7722214.
DOI: 10.1111/jth.15014.
Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.
Jawi M, Frohlich J, Chan S
J Lipids. 2020; 2020:3491764.
PMID: 32099678
PMC: 7016456.
DOI: 10.1155/2020/3491764.
Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis.
Wang Z, Zhai X, Xue M, Cheng W, Hu H
Lipids Health Dis. 2019; 18(1):150.
PMID: 31286992
PMC: 6615167.
DOI: 10.1186/s12944-019-1092-6.
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?.
Boffa M, Koschinsky M
J Lipid Res. 2015; 57(5):745-57.
PMID: 26647358
PMC: 4847635.
DOI: 10.1194/jlr.R060582.
Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a).
Krychtiuk K, Kastl S, Hofbauer S, Wonnerth A, Goliasch G, Ozsvar-Kozma M
J Clin Lipidol. 2015; 9(4):533-41.
PMID: 26228671
PMC: 4533224.
DOI: 10.1016/j.jacl.2015.04.005.
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).
Romagnuolo R, Marcovina S, Boffa M, Koschinsky M
J Lipid Res. 2014; 55(4):625-34.
PMID: 24478033
PMC: 3966697.
DOI: 10.1194/jlr.M036566.
Lipoprotein(a) serum levels in diabetic patients with retinopathy.
Malaguarnera G, Gagliano C, Bucolo C, Vacante M, Salomone S, Malaguarnera M
Biomed Res Int. 2013; 2013:943505.
PMID: 23862162
PMC: 3687764.
DOI: 10.1155/2013/943505.
Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a).
Kyutoku M, Nakagami H, Koriyama H, Nakagami F, Shimamura M, Kurinami H
Sci Rep. 2013; 3:1600.
PMID: 23549288
PMC: 3615337.
DOI: 10.1038/srep01600.